1Semana·

Thermo Fisher Q2'25 Earnings Highlights

$TMO (-2,68 %)


🔹 Revenue: $10.86B (Est. $10.69B) 🟢; UP +3% YoY

🔹 Organic Revenue Growth: +2% (Est. +0.8%) 🟢

🔹 Adj. EPS: $5.36 (Est. $5.24) 🟢

🔹 Adj. OI: $2.38B; UP from $2.35B YoY


Strategic & Product Highlights

🔹 Launched next-gen mass spectrometers: Orbitrap™ Astral™ Zoom, Excedion™ Pro, and Krios™ 5 Cryo-TEM

🔹 Expanded DynaDrive™ bioreactor portfolio with new bench-scale system

🔹 Accelerator™ Drug Development solution validated by Tufts Center study

🔹 Expanded U.S. sterile fill-finish capacity via Sanofi Ridgefield site acquisition


CEO Commentary

🔸 “Our exceptional team continues to execute at a high level, enabling customer success while navigating the macroenvironment.”

🔸 “Trusted partner status and agility of our PPI Business System help us adapt, manage costs, and gain market share.”

🔸 “We’re on track to meet 2025 commitments and building a brighter future for Thermo Fisher.”


Outlook

🔸 Updated FY25 guidance to be provided during earnings call

9
Únase a la conversación